Search

Displaying results 3961 - 3970 of 10000 in total
  1. Drug

    Mito-4509

    go.drugbank.com/drugs/DB05846
    Experimental

    It is used to treat Parkinson's Disease, Alzheimer's Disease, Retinal Disorders and other neurologic Disorders. … Mito-4509 is a non-feminizing estrogen analog that could affect mitochondrial metabolic pathways.

  2. Drug

    Desoxycorticosterone pivalate

    go.drugbank.com/drugs/DB01134
    ExperimentalVet approved

    It is practically insoluble in water, sparingly soluble in acetone, slightly soluble in methanol, ether and vegetable oils. … Desoxycorticosterone pivalate is a mineralocorticoid hormone and an analog of desoxycorticosterone. It is white, odorless, and stable in air.

  3. Drug

    Influenza B virus B/Darwin/7/2019 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15709
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  4. Drug

    DAS-431 IV

    go.drugbank.com/drugs/DB05432
    Experimental

    DAS-431 IV is a dopamine D1 receptor agonist developed by DrugAbuse Sciences for the treatment of Addictions, Schizophrenia, Schizoaffective Disorders, Dementia, Parkinson's Disease, Strokes etc.

  5. Drug

    Eliprodil

    go.drugbank.com/drugs/DB12869
    Investigational

    Eliprodil has been used in trials studying the treatment of Parkinson Disease and Movement Disorders.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Emicizumab

    go.drugbank.com/drugs/DB13923
    ApprovedInvestigational

    Emicizumab was originated as an improved form of hBS23 and it was approved on November 16, 2017.[A31279, L1016] It was created by Chugai Pharmaceuticals Co. … Emicizumab is a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and it has the capacity to bind simultaneously to activated Factor IX and Factor X.

  7. Drug

    UCB-1184197

    go.drugbank.com/drugs/DB05092
    Investigational

    CDP323 is an antagonist of the _vascular cell adhesion molecule 1_ (VCAM-1) binding to alpha4-integrins (other adhesion molecules), a process thought to be implicated in the pathophysiology of Multiple … It is considered a small-molecule prodrug. CDP323 was originally developed by the British biopharmaceutical company Celltech plc.

  8. Drug

    JSM 6427

    go.drugbank.com/drugs/DB06139
    Investigational

    It has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness in people over the age of 55. … JSM 6427 is the first small molecule alpha5beta1 integrin receptor antagonist of its kind to be developed.

  9. Drug

    Ordopidine

    go.drugbank.com/drugs/DB05196
    Investigational

    ACR325 is a dopaminergic stabiliser, which has demonstrated promising results in disease models for motor functions and psychoses. … ACR325 is developed for the treatment of Parkinson’s disease and psychoses, including bipolar disorder, for which disease existing therapies have only limited effect and considerable adverse side effects

  10. Drug

    R343

    go.drugbank.com/drugs/DB06316
    Investigational

    R343, was investigated in clinical trial NCT01591044 to evaluate its safety and efficacy in patients with mild to moderate asthma.

    Synonyms: 2- {3- [4-(2,2-Difluoro-3 -oxo-3,4-dihydro-2H-benzo [1,4] oxazin-6-ylamino)5-fluoro-pyrimidin-2-ylamino]phenoxy}N-methyl-acetamide